A
Anavo Therapeutics
Phosphatase-targeted allosteric modulators for oncology therapeutics.
About Anavo Therapeutics
Anavo Therapeutics is a biopharmaceutical company focused on systematically drugging phosphatases, a class of enzymes long considered undruggable. The company was founded in 2020 with operations starting in 2021, and is led by co-founders Dr. Birgit Zech (CEO) and Dr. Gerhard Müller (CSO), who previously collaborated as co-founders of Gotham Therapeutics. The founding team also includes Claus Schalper, a finance expert and serial biotech entrepreneur. Headquartered in Leiden, Netherlands, Anavo also operates an R&D hub in Heidelberg, Germany, to leverage proximity to major European research centers.
The company's core asset is its proprietary IGNITE platform, which is engineered to discover and develop allosteric modulators that target phosphatases. Unlike kinase inhibitors, which have become a multi-billion dollar market, phosphatases have been a challenging target class. Anavo's approach bypasses the enzymes' active sites, combining deep knowledge of phosphatase biology with high-throughput screening and advanced protein structural methods to create first-in-class small molecule drugs. The primary therapeutic focus for its in-house pipeline is oncology, with plans to expand into other indications through strategic partnerships.
Anavo Therapeutics launched in April 2021 with a significant seed financing round of €20 million (approximately $24 million), co-led by M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures. The company extended this seed round in May 2023, raising an additional €8.5 million and bringing the total to €28 million (approximately $33.3 million). This extension introduced MRL Ventures Fund, the venture arm of Merck & Co., Inc., as a new investor. These funds are designated to advance the company's proprietary oncology programs towards clinical development and to further build out its IGNITE platform.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | May 2023 | $9.3M | $120M | Inkef · M Ventures · Bioqube Ventures · Taiho Pharma | ↗ |
| SEED✓Equity / VC | Apr 2021 | $24M | $96M | Inkef · Bioqube Ventures · M Ventures · Taiho Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Anavo Therapeutics is 1.7K monthly website visits, up 107.3% over the last three months. Anavo Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Anavo Therapeutics in the Leiden ecosystem
The Anavo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Inkef
Bioqube Ventures
M Ventures- TVTaiho Ventures
Taiho Pharma
MRL Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Anavo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Anavo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








